SEARCH

SEARCH BY CITATION

References

  • 1
    Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. Evidence for the use of intravenous immunoglobulins – a review of the literature. Clin Rev Allergy Immunol 2010; 38:20169.
  • 2
    Orange JS, Hossny EM, Weiler CR et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117 (Suppl.):S52553.
  • 3
    Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008; 28:80319, ix.
  • 4
    Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, the Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26:26573.
  • 5
    Gardulf A, Nicolay U, Asensio O et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies – a prospective, multi-national study. J Clin Immunol 2006; 26:17785.
  • 6
    Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20:94100.
  • 7
    Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 2007; 96:14748.
  • 8
    Chouksey A, Duff K, Wasserbauer N, Berger M. Subcutaneous immunoglobulin-G replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens. Allergy Asthma Clin Immunol 2005; 1:12030.
  • 9
    Nicolay U, Kiessling P, Berger M et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006; 26:6572.
  • 10
    Kittner JM, Grimbacher B, Wulff W, Jäger B, Schmidt RE. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 2006; 26:4005.
  • 11
    Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol 2008; 28:3708.
  • 12
    Gardulf A, Borte M, Ochs HD, Nicolay U, the Vivaglobin Clinical Study Group. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2008; 126:818.
  • 13
    Gardulf A, Nicolay U, Math D et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114:93642.
  • 14
    Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987; 1:10757.
  • 15
    Quartier P, Debré M, De Blic J et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999; 134:58996.
  • 16
    Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122:21012.
  • 17
    Bonilla FA, Bernstein IL, Khan DA et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94 (5 Suppl. 1):S163.
  • 18
    Eijkhout HW, Van Der Meer JWM, Kallenberg CGM et al. for the Inter-University Working Party for the Study of Immune Deficiencies. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001; 135:16574.
  • 19
    Gelfand EW, Hanna K, the IGIV-C Increased Maximum Infusion Rate Study Group. Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients. J Clin Immunol 2006; 26:28490.
  • 20
    Roifman CM, Schroeder H, Berger M et al., the IGIV-C in PID Study Group. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: a randomized double-blind trial. Int Immunopharmacol 2003; 3:132533.
  • 21
    Ballow M, Berger M, Bonilla FA et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang 2003; 84:20210.
  • 22
    Waniewski J, Gardulf A, Hammarström L. Bioavailability of γ-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994; 14:907.
  • 23
    Smith GN, Griffiths B, Mollison D, Mollison PL. Uptake of IgG after intramuscular and subcutaneous injection. Lancet 1972; 1:120812.
  • 24
    Vivaglobin [package insert]. Marburg, Germany: CSL Behring GmbH, 2007.
  • 25
    US Department of Health and Human Services. Safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Washington, DC: US Department of Health and Human Services, 2008.
  • 26
    Hughes RAC, Donofrio P, Bril V et al. on behalf of the ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7:13644.
  • 27
    Bril V, Katzberg H, Donofrio P et al. Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 2009; 39:44855.
  • 28
    Merkies ISJ, Bril V, Dalakas MC et al. on behalf of the ICE Study Group. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study. Neurology 2009; 72:133744.
  • 29
    Aebersold P. Regulatory requirements for subcutaneous Ig for PID. In: US Department of Health and Human Services, eds. Intravenous immune globulins in the 21st century: progress and challenges in efficacy, safety, and paths to licensure. Bethesda, MD: US Department of Health and Human Services, 2005. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/TranscriptsMinutes/UCM054437.pdf (accessed 16 October 2009).
  • 30
    Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008; 28:779802, vii.
  • 31
    Desai S, Poll J, Chouksey A, Berger M. Randomized, crossover study of the efficacy and tolerability of the same dose of Gamunex® given subcutaneously or intravenously. J Allergy Clin Immunol 2008; 121:85.
  • 32
    Gustafson R, Gardulf A, Hansen S et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol 2008; 152:2749.